| scholarly article | Q13442814 |
| P50 | author | Derek LeRoith | Q5262136 |
| Keith Sigel | Q42246426 | ||
| Juan P Wisnivesky | Q88007708 | ||
| P2093 | author name string | Matthew D Galsky | |
| Cardinale B Smith | |||
| Emily J Gallagher | |||
| Grace Mhango | |||
| Jenny J Lin | |||
| P2860 | cites work | Metformin in Cancer Therapy: A New Perspective for an Old Antidiabetic Drug? | Q22241958 |
| Molecular mechanism of action of metformin: old or new insights? | Q22252798 | ||
| Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review | Q26850912 | ||
| Shifting from the single to the multitarget paradigm in drug discovery | Q27144242 | ||
| AMPK: a nutrient and energy sensor that maintains energy homeostasis | Q29615410 | ||
| Development of a comorbidity index using physician claims data | Q30623996 | ||
| Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population | Q30714715 | ||
| Utility of the SEER-Medicare data to identify chemotherapy use. | Q30714828 | ||
| Data sources for measuring comorbidity: a comparison of hospital records and medicare claims for cancer patients | Q31062334 | ||
| Studying radiation therapy using SEER-Medicare-linked data | Q33184144 | ||
| Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. | Q33859224 | ||
| Metformin and breast cancer risk: a meta-analysis and critical literature review | Q34357389 | ||
| Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases | Q34439990 | ||
| Diabetes mellitus and risk of colorectal cancer: a meta-analysis | Q34562613 | ||
| Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission | Q34611836 | ||
| Diabetes mellitus and risk of breast cancer: a meta-analysis | Q34614029 | ||
| Clinically defined type 2 diabetes mellitus and prognosis in early-stage breast cancer | Q34662865 | ||
| Metformin decreases the dose of chemotherapy for prolonging tumor remission in mouse xenografts involving multiple cancer cell types | Q34899382 | ||
| Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. | Q34904669 | ||
| Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis | Q34976375 | ||
| Survival and risk of adverse events in older patients receiving postoperative adjuvant chemotherapy for resected stages II-IIIA lung cancer: observational cohort study | Q35104573 | ||
| Metformin Prevents Tobacco Carcinogen–Induced Lung Tumorigenesis | Q35333423 | ||
| Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival | Q35688186 | ||
| Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer | Q35819793 | ||
| Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis | Q35842470 | ||
| Diabetes and cause-specific mortality in a prospective cohort of one million U.S. adults | Q36181365 | ||
| The effect of metformin and thiazolidinedione use on lung cancer in diabetics | Q36453693 | ||
| Validity of a prescription claims database to estimate medication adherence in older persons | Q36461386 | ||
| The use of metformin and the incidence of lung cancer in patients with type 2 diabetes | Q36477885 | ||
| A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients | Q36832684 | ||
| Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK. | Q36896122 | ||
| Diabetes complications severity index and risk of mortality, hospitalization, and healthcare utilization | Q37260160 | ||
| Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line | Q37326781 | ||
| Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. | Q37413146 | ||
| Repositioning metformin for cancer prevention and treatment | Q38114964 | ||
| Cancer drug discovery by repurposing: teaching new tricks to old dogs | Q38127534 | ||
| The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis | Q38181612 | ||
| Metformin does not alter the risk of lung cancer: a case-control analysis. | Q38430462 | ||
| Metformin inhibits heme oxygenase-1 expression in cancer cells through inactivation of Raf-ERK-Nrf2 signaling and AMPK-independent pathways | Q39147542 | ||
| Metformin-mediated downregulation of p38 mitogen-activated protein kinase-dependent excision repair cross-complementing 1 decreases DNA repair capacity and sensitizes human lung cancer cells to paclitaxel | Q39228631 | ||
| Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth | Q46603046 | ||
| Using inverse probability-weighted estimators in comparative effectiveness analyses with observational databases | Q81382203 | ||
| Prognostic influence of metformin as first-line chemotherapy for advanced nonsmall cell lung cancer in patients with type 2 diabetes | Q83979505 | ||
| Diabetes mellitus negatively impacts survival of patients with colon cancer, particularly in stage II disease | Q84049962 | ||
| Metformin induces apoptosis of lung cancer cells through activating JNK/p38 MAPK pathway and GADD153 | Q84897945 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| lung cancer | Q47912 | ||
| P304 | page(s) | 448-454 | |
| P577 | publication date | 2015-02-01 | |
| P1433 | published in | American Journal of Respiratory and Critical Care Medicine | Q4744267 |
| P1476 | title | Survival of patients with stage IV lung cancer with diabetes treated with metformin | |
| P478 | volume | 191 |
| Q90192600 | A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer |
| Q52682466 | A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. |
| Q58793875 | Diabetes induces fibrotic changes in the lung through the activation of TGF-β signaling pathways |
| Q104802889 | Diethyldithiocarbamate-copper complex (CuET) inhibits colorectal cancer progression via miR-16-5p and 15b-5p/ALDH1A3/PKM2 axis-mediated aerobic glycolysis pathway |
| Q48611342 | Do male esophageal cancer patients have impaired sexual function after esophagectomy? A self-reported outcomes study |
| Q46018831 | Effect of Angiotensin System Inhibitors on Survival in Patients Receiving Chemotherapy for Advanced Non-Small-Cell Lung Cancer. |
| Q55177909 | Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis. |
| Q35803926 | Effects of metformin on survival outcomes of lung cancer patients with type 2 diabetes mellitus: a meta-analysis |
| Q64117465 | Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy |
| Q49788560 | High glucose contributes to the proliferation and migration of non-small cell lung cancer cells via GAS5-TRIB3 axis |
| Q39040854 | Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity? |
| Q42700947 | Integrated analysis of dosage effect lncRNAs in lung adenocarcinoma based on comprehensive network |
| Q47767194 | Metformin Has Positive Therapeutic Effects in Colon Cancer and Lung Cancer |
| Q37294190 | Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis |
| Q36774352 | Metformin Protects Against Cisplatin-Induced Tubular Cell Apoptosis and Acute Kidney Injury via AMPKα-regulated Autophagy Induction |
| Q58699189 | Metformin and blood cancers |
| Q47761912 | Metformin as a repurposed therapy in advanced non-small cell lung cancer (NSCLC): results of a phase II trial. |
| Q61800968 | Metformin enhances the radiosensitizing effect of cisplatin in non-small cell lung cancer cell lines with different cisplatin sensitivities |
| Q39290525 | Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies |
| Q47106766 | Metformin induces cell cycle arrest at the G1 phase through E2F8 suppression in lung cancer cells |
| Q37376577 | Metformin therapy associated with survival benefit in lung cancer patients with diabetes |
| Q36103093 | Metformin use and its effect on survival in diabetic patients with advanced non-small cell lung cancer |
| Q103826245 | Metformin use and lung cancer survival: a population-based study in Norway |
| Q38734576 | Metformin use and survival after non-small cell lung cancer: A cohort study in the US Military health system |
| Q40930334 | Metformin use improves the survival of diabetic combined small-cell lung cancer patients |
| Q38756907 | Metformin: A Hopeful Promise in Aging Research |
| Q36980520 | PolyMetformin combines carrier and anticancer activities for in vivo siRNA delivery |
| Q37061329 | Pre-existing diabetes and lung cancer prognosis |
| Q40847551 | Prognosis of small cell lung cancer patients with diabetes treated with metformin |
| Q55171668 | Prognostic value of metformin for non-small cell lung cancer patients with diabetes. |
| Q39321321 | Progress in the application and mechanism of metformin in treating non-small cell lung cancer |
| Q41191101 | Sex-dependent difference in the effect of metformin on colorectal cancer-specific mortality of diabetic colorectal cancer patients. |
| Q48252582 | Survival benefit associated with metformin use in inoperable non-small cell lung cancer patients with diabetes: A population-based retrospective cohort study |
| Q41242882 | The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies |
| Q92281751 | The Effect of Metformin on Mortality Among Diabetic Cancer Patients: A Systematic Review and Meta-analysis |
| Q58591029 | The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC |
| Q99365521 | The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer |
| Q38728567 | The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development |
| Q90541158 | The prognostic value of metformin for advanced non-small cell lung cancer: a systematic review and meta-analysis |
| Q35915762 | Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again |
| Q38930166 | Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas |
Search more.